Literature DB >> 18810998

Evaluation of lipoxygenase inhibitory activity of anacardic acids.

Isao Kubo1, Tae Joung Ha, Kazuo Tsujimoto, Felismino E Tocoli, Ivan R Green.   

Abstract

6-Alkylsalicylic acids inhibit the linoleic acid peroxidation catalyzed by soybean lipoxygenase-1 (EC 1.13.11.12, type 1) competitively and without pro-oxidant effects. This activity is largely dependent on the nature of their alkyl side chains. Inhibitory activities of anacardic acids, viz. 6-pentadec(en)ylsalicylic acids, isolated from the cashew Anacardium occidentale, were initially used for comparison because their aromatic head portions are the same. Consequently, the data should be interpreted to mean that changes in the hydrophobic side chain tail portions of the molecules evaluated correlate with the specific activity determined.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810998     DOI: 10.1515/znc-2008-7-812

Source DB:  PubMed          Journal:  Z Naturforsch C J Biosci        ISSN: 0341-0382


  4 in total

Review 1.  Biological activity of phenolic lipids.

Authors:  Maria Stasiuk; A Kozubek
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

Review 2.  Potential biological applications of bio-based anacardic acids and their derivatives.

Authors:  Fatma B Hamad; Egid B Mubofu
Journal:  Int J Mol Sci       Date:  2015-04-16       Impact factor: 5.923

3.  Superoxide anion scavenging activity of alk(en)yl phenol compounds by using PMS-NADH system.

Authors:  Noriyoshi Masuoka; Kulwadee Tamsampaoloet; Warinthorn Chavasiri; Isao Kubo
Journal:  Heliyon       Date:  2016-10-01

4.  Antioxidant and Anti-Inflammatory Properties of Anacardium occidentale Leaf Extract.

Authors:  Natália Cabral Souza; Juliana Medeiros de Oliveira; Maurílio da Silva Morrone; Ricardo D'Oliveira Albanus; Maria do Socorro Medeiros Amarante; Christina da Silva Camillo; Silvana Maria Zucolotto Langassner; Daniel Pens Gelain; José Cláudio Fonseca Moreira; Rodrigo Juliani Siqueira Dalmolin; Matheus Augusto de Bittencourt Pasquali
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-17       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.